Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service aneurysm & intracranial embolization cases in North Carolina: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 13% on average (82 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 6 | 282 | 40% |
| 2020 | 8 | 280 | 43% |
| 2021 | 9 | 305 | 48% |
| 2022 | 9 | 316 | 52% |
| 2023 | 7 | 293 | 56% |
| 2024 | 13 | 383 | 59% |
| 2025 from claims | – | 427 345–501 | 61% |
| 2026 forecast | – | 464 364–583 | 62% |
| 2027 forecast | – | 502 373–664 | 62% |
| 2028 forecast | – | 544 385–750 | 63% |
| 2029 forecast | – | 588 400–843 | 64% |
| 2030 forecast | – | 635 416–943 | 65% |
Aneurysm coiling and flow diversion, AVM and tumor embolization, intracranial stenting. Professional codes (what the surgeon bills): CPT 61624, 61635, 61630.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 86% of the cases CMS names in North Carolina; 9 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 95% inpatient hospital, 5% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~460 | ~440 | ~20 |
| 2027 · ~500 | ~480 | ~21 |
| 2028 · ~540 | ~520 | ~22 |
The forecast’s cases at the projected mix.
The mix is steady: the trend moves no setting by a point or more by 2028.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 40 | 1,299+18%/yr | +18%/yr | 0.6 | 0% | 2,280 in 2030+9.8%/yr |
| Texas | 28 | 1,099+13%/yr | +13%/yr | 0.5 | 0% | 2,130 in 2030+12%/yr |
| Virginia | 11 | 407+13%/yr | +13%/yr | 0.4 | 0% | 670 in 2030+8.8%/yr |
| Tennessee | 9 | 328+6.6%/yr | +6.6%/yr | 0.5 | 0% | 490 in 2030+6.8%/yr |
| Maryland | 10 | 326+15%/yr | +15%/yr | 0.4 | 0% | 570 in 2030+9.9%/yr |
| Georgia | 8 | 323+8.8%/yr | +8.8%/yr | 0.4 | 0% | 940 in 2030+19%/yr |
| Kentucky | 9 | 226+16%/yr | +16%/yr | 0.5 | 0% | 310 in 2030+5.4%/yr |
| Alabama | 6 | 196+34%/yr | +34%/yr | 0.4 | 0% | 300 in 2030+7.4%/yr |
| South Carolina | 9 | 195−0.2%/yr | −0.2%/yr | 0.3 | 0% | 440 in 2030+15%/yr |
| Oklahoma | 2 | 164+3.5%/yr | +3.5%/yr | 0.3 | 0% | 450 in 2030+18%/yr |
| Louisiana | 7 | 162+8.9%/yr | +8.9%/yr | 0.4 | 0% | 220 in 2030+5%/yr |
| Mississippi | 4 | 119+13%/yr | +13%/yr | 0.3 | 0% | 110 in 2030−1.2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Stroke thrombectomy | 15 | 435−2.3%/yr | −2.3%/yr | 0.51.1× | 0% | 420 in 2030−0.8%/yr |
| DBS & VNS | 8 | 293−8.9%/yr | −8.9%/yr | 0.30.9× | 0% | 440 in 2030+7.1%/yr |
| CSF shunts | 2 | 190−7.9%/yr | −7.9%/yr | 0.21.0× | 0% | 170 in 2030−1.6%/yr |
Aneurysm & intracranial embolization in every state, and its device makers · Every procedure market in North Carolina · Every state · Compare with Florida
Penumbra leads with 43% of company spending on these surgeons in 2025, +22 pts on 2024.
In 2025, 12 companies reported engagement with North Carolina’s surgeons worth $113K in consulting, speaking, meals and travel tied to these products, about $8,666 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
For CPT 61624 (transcath occlusion cns), commercial plans pay North Carolina’s hospitals a median of $18K, from $14K at the lowest to $18K at the highest, across 8 hospitals that publish a price.
Each hospital’s median over its commercial plans, from the machine-readable files hospitals must post; not every hospital is loaded.